JP2024517917A - Ｎｌｒｐ３阻害剤 - Google Patents

Ｎｌｒｐ３阻害剤 Download PDF

Info

Publication number
JP2024517917A
JP2024517917A JP2023569634A JP2023569634A JP2024517917A JP 2024517917 A JP2024517917 A JP 2024517917A JP 2023569634 A JP2023569634 A JP 2023569634A JP 2023569634 A JP2023569634 A JP 2023569634A JP 2024517917 A JP2024517917 A JP 2024517917A
Authority
JP
Japan
Prior art keywords
methyl
triazin
amino
phenyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517917A5 (https=
Inventor
ブッシュ，レア・オレリー
グーバ，ヴォルフガング
ヤーシュケ，ゲオルク
メッシュ，ステファニー・カタリナ
トストルフ，アンドレアス・ミヒャル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2024517917A publication Critical patent/JP2024517917A/ja
Publication of JP2024517917A5 publication Critical patent/JP2024517917A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2023569634A 2021-05-12 2022-05-10 Ｎｌｒｐ３阻害剤 Pending JP2024517917A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21173452.0 2021-05-12
EP21173452 2021-05-12
EP21209447 2021-11-22
EP21209447.8 2021-11-22
EP21215859.6 2021-12-20
EP21215859 2021-12-20
PCT/EP2022/062525 WO2022238347A1 (en) 2021-05-12 2022-05-10 Nlrp3 inhibitors

Publications (2)

Publication Number Publication Date
JP2024517917A true JP2024517917A (ja) 2024-04-23
JP2024517917A5 JP2024517917A5 (https=) 2025-04-30

Family

ID=81941106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569634A Pending JP2024517917A (ja) 2021-05-12 2022-05-10 Ｎｌｒｐ３阻害剤

Country Status (25)

Country Link
US (1) US20240208928A1 (https=)
EP (2) EP4337652B1 (https=)
JP (1) JP2024517917A (https=)
KR (1) KR20240007152A (https=)
AR (1) AR125818A1 (https=)
AU (1) AU2022275300A1 (https=)
BR (1) BR112023023527A2 (https=)
CA (1) CA3214626A1 (https=)
CL (1) CL2023003312A1 (https=)
CO (1) CO2023016204A2 (https=)
CR (1) CR20230529A (https=)
DK (1) DK4337652T3 (https=)
ES (1) ES3031704T3 (https=)
FI (1) FI4337652T3 (https=)
HR (1) HRP20250632T1 (https=)
HU (1) HUE071498T2 (https=)
IL (1) IL307188A (https=)
LT (1) LT4337652T (https=)
MA (1) MA64323B1 (https=)
MX (1) MX2023012907A (https=)
PE (1) PE20240126A1 (https=)
PL (1) PL4337652T3 (https=)
RS (1) RS66893B1 (https=)
SI (1) SI4337652T1 (https=)
WO (1) WO2022238347A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
IL314025A (en) * 2022-01-07 2024-08-01 Transthera Sciences Nanjing Inc Nlrp3 inflammasome inhibitor and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
AU2023371859A1 (en) * 2022-11-04 2025-06-12 Transthera Sciences (Nanjing) , Inc. Nlrp3 inflammasome inhibitor and use thereof
PE20251845A1 (es) * 2022-12-07 2025-07-17 Hoffmann La Roche Compuestos novedosos como moduladores de la inhibicion de nlrp3
WO2024158941A2 (en) * 2023-01-27 2024-08-02 Mwyngil Therapeutics, Inc. Inhibitors of nlrp3
JP2026511027A (ja) * 2023-03-20 2026-04-10 インシリコ メディスン アイピー リミティド Ｎｌｒｐ３インフラマソーム阻害剤及びその使用
WO2024193699A1 (zh) 2023-03-23 2024-09-26 成都赜灵生物医药科技有限公司 三嗪类化合物及其用途
KR20260027946A (ko) 2023-06-02 2026-03-03 머크 샤프 앤드 돔 엘엘씨 Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클
IL324489A (en) 2023-06-29 2026-01-01 Hoffmann La Roche Triazine derivatives as NLRP3 inhibitors
CN121586712A (zh) 2023-07-28 2026-02-27 豪夫迈·罗氏有限公司 新颖化合物
WO2025059069A1 (en) * 2023-09-12 2025-03-20 Zomagen Biosciences Ltd Nlrp3 modulators
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020234715A1 (en) * 2019-05-17 2020-11-26 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653316B1 (en) * 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020234715A1 (en) * 2019-05-17 2020-11-26 Novartis Ag Nlrp3 inflammasome inhibitors

Also Published As

Publication number Publication date
MX2023012907A (es) 2023-11-08
PL4337652T3 (pl) 2025-07-14
TW202311245A (zh) 2023-03-16
SI4337652T1 (sl) 2025-07-31
RS66893B1 (sr) 2025-07-31
EP4337652B1 (en) 2025-04-09
LT4337652T (lt) 2025-06-25
EP4609865A3 (en) 2025-10-29
KR20240007152A (ko) 2024-01-16
DK4337652T3 (da) 2025-06-10
AR125818A1 (es) 2023-08-16
BR112023023527A2 (pt) 2024-01-30
CA3214626A1 (en) 2022-11-17
AU2022275300A1 (en) 2023-09-21
MA64323B1 (fr) 2025-06-30
ES3031704T3 (en) 2025-07-10
EP4609865A2 (en) 2025-09-03
PE20240126A1 (es) 2024-01-22
EP4337652A1 (en) 2024-03-20
US20240208928A1 (en) 2024-06-27
FI4337652T3 (fi) 2025-06-20
HUE071498T2 (hu) 2025-09-28
WO2022238347A1 (en) 2022-11-17
HRP20250632T1 (hr) 2025-07-18
CR20230529A (es) 2023-12-04
IL307188A (en) 2023-11-01
CL2023003312A1 (es) 2024-06-21
CO2023016204A2 (es) 2023-12-11

Similar Documents

Publication Publication Date Title
US20240208928A1 (en) Novel compounds
JP7705963B2 (ja) トリアジン誘導体およびがんの処置におけるその使用
TWI850648B (zh) 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
AU2014358792B2 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
AU2015261812B2 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
JP2024540445A (ja) 複素環式ｎｌｒｐ３阻害剤
US11702414B2 (en) Thiadiazole IRAK4 inhibitors
JP2025519226A (ja) 新規化合物
JP2025537238A (ja) Ｎｌｒｐ３阻害剤としてのトリアジノン誘導体
JP2025539252A (ja) Ｎｌｒｐ３阻害剤としてのトリアジノン誘導体
JP2025540258A (ja) Ｎｌｒｐ３の阻害剤
CN117794910A (zh) Nlrp3抑制剂
TWI915553B (zh) 新穎化合物、包含其之組成物以及相關製備方法及醫藥用途
EA052779B1 (ru) Триазиновые производные и их применение в лечении рака
HK40104195A (zh) Nlrp3抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260401

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260428